Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in EpidermolysisBullosa 08-Oct-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art.
This is how ABEO’s leading candidate, Pz-cel, targets recessive dystrophic epidermolysisbullosa [RDEB]. Pz-cel is working towards FDA approval and is expected to resubmit the BLA in 2H2024.
Carol Schober-Flores, BSN, RN, is a Mohs Surgical Nurse and EpidermolysisBullosa Nurse Specialist, University Hospital, Denver, CO. Topical ointments can be applied directly over the Mepitel ...